Metastatic gastric cancer from malignant fibrous histiocytoma

Ibáñez, J.A. Contreras; García, Natalia Navas; Gómez, L. Díaz

doi:10.4321/s1130-01082011000100012

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In around 50% of cases the lower limbs are involved, in 24% the upper limbs, in 16% the trunk, and in almost 10% the retroperitoneum 6 . Occasionally these tumors may be found in any part of the body, including the digestive tract, spermatic cord, kidney, pancreas, spleen, lung, thymus, ovaries, and gallbladder 1,2 .…”

Section: Discussionmentioning

confidence: 99%

“…First described by O'Brien and Stout 1 , MFH is usually large, high grade, and biologically aggressive. Although it can appear virtually anywhere, it is not surprising that these tumors can arise in bone, according to very few published reports 2,3 . Only 5% of all skeletal primary malignant tumors are MFH [1][2][3] .…”

Section: Introductionmentioning

confidence: 99%

“…Although it can appear virtually anywhere, it is not surprising that these tumors can arise in bone, according to very few published reports 2,3 . Only 5% of all skeletal primary malignant tumors are MFH [1][2][3] . The majority of these cases have been described in isolated case reports or small series.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Major Response to Trabectedin in Metastatic Malignant Fibrous Histiocytoma of the Vertebra: A Case Report and Review of the Literature

Sereno

Merino

Aguayo

et al. 2013

Tumori

View full text Add to dashboard Cite

Malignant fibrous histiocytoma is an aggressive tumor, the most common soft-tissue sarcoma of adult age. It is usually located in the extremities and retroperitoneum, and very rarely there is skeletal involvement. Surgery is the preferred treatment in early disease; in advanced disease, chemotherapy is the main therapeutic strategy. We present a 25-year-old female patient diagnosed with a vertebral mass in T5 with a severely compromised spinal cord. She underwent surgical decompression and the pathological findings were consistent with malignant fibrous histiocytoma. After several surgical treatments she had pulmonary progression and was therefore started on chemotherapy. She had a very poor response to most of the administered regimens until she initiated trabectedin 1 mg/m 2 every three weeks. She showed a significant improvement with a major response of the lung metastases. This report indicates that trabectedin is an active drug in advanced, previously treated metastatic malignant fibrous histiocytoma.

show abstract

Section: Discussionmentioning

confidence: 99%